Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer—A review
- 18 June 2011
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 129 (5) , 1031-1041
Abstract
Adjuvant first‐line gemcitabine monochemotherapy presents a standard treatment for patients with advanced pancreatic adenocarcinoma and improves overall survival in chemosensitive patients. Nonetheless, 6‐month progression‐free survival remains below 15%, despite interdisciplinary approaches. The success of gemcitabine treatment is disappointing and—in the absence of reliable tumor markers—challenging to quantify. Epigenetic alterations have been recently identified to take on important roles in cancer development and possibly cancer treatment. In this context, microRNAs are becoming increasingly acknowledged as useful biomarkers for classifying cancers and providing information on their chemo‐ and radiosensitivity. This review illustrates the potential of genetic and epigenetic markers in the prediction of chemosensitivity in pancreatic cancer patients and in the monitoring of their response rates to adjuvant therapy.Keywords
This publication has 101 references indexed in Scilit:
- Roles and Mechanisms of MicroRNAs in Pancreatic CancerWorld Journal of Surgery, 2011
- Implication of microRNAs in drug resistance for designing novel cancer therapyDrug Resistance Updates, 2010
- Harnessing the fruits of nature for the development of multi-targeted cancer therapeuticsCancer Treatment Reviews, 2009
- Cellular signaling perturbation by natural productsCellular Signalling, 2009
- Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem CellsCell, 2009
- Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer ModelCell, 2009
- Origins and Mechanisms of miRNAs and siRNAsCell, 2009
- MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon AdenocarcinomaJAMA, 2008
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006